Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-0261 in Moderate to Severe Active Ulcerative Colitis
NCT07744646Phase 1Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Aug 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Alpha-0261 in ulcerative colitis (UC), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Treatment-Related Adverse Events at 12 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Alpha-0261
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07744646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744646.